AntiInfectiveMeds
Since 2010
| Quantity | Price per capsule | You save | Total price | |
|---|---|---|---|---|
| 30 | A$5.07 | - | A$152.00 | |
| 60 | A$3.88 | A$71.44 | A$232.56 |
Your order is carefully packed and ships within 24 hours. Here is what a typical package looks like.
Sized like a regular personal letter (approximately 24x11x0.7 cm), with no indication of what is inside.
| Delivery Method | Estimated delivery |
|---|---|
| Express Free for orders over A$456.00 | Estimated delivery to Australia: 4-7 days |
| Standard Free for orders over A$304.00 | Estimated delivery to Australia: 14-21 days |
Indinavir 400 mg capsules belong to the protease-inhibitor class of antiretroviral medicines, but two practical features distinguish this option from several other medicines used for HIV-1 infection. First, Indinavir does not have the sulfonamide structure found in protease inhibitors such as darunavir, fosamprenavir and tipranavir. This means it does not present the same structural concern for someone with an unspecified history of sulfonamide allergy, although allergies to Indinavir itself or any capsule ingredient still require individual assessment. Second, food can substantially affect Indinavir absorption, so the timing of each dose in relation to meals is an important part of treatment.
These distinctions do not make Indinavir universally preferable. They create a specific trade-off: it may avoid one structural allergy consideration, but its meal-timing requirements and kidney-stone risk can make the routine less suitable for some people. A useful comparison therefore considers the complete regimen, health history and ability to follow the prescribed schedule consistently.
Indinavir capsules are used to treat HIV-1 infection in adults in combination with other antiretroviral medicines. They are not used as a standalone treatment. Combination therapy targets HIV replication at more than one stage and reduces the likelihood that the virus will become resistant to a single medicine.
A regimen may include medicines from other antiretroviral classes, such as nucleoside reverse transcriptase inhibitors. Epivir, which contains lamivudine, is an example from that class, but naming it does not mean it is the appropriate companion medicine for every Indinavir regimen. The entire combination must be selected by a clinician who can assess resistance history, previous treatment, interactions, organ function and the practical demands of taking each medicine.
Indinavir was among the earlier HIV protease inhibitors. Its established role does not remove the need to compare it with current alternatives, especially because antiretroviral treatment standards and the availability of individual products can change. The relevant decision is whether this exact 400 mg oral capsule fits the complete regimen proposed for the individual patient.
Indinavir has established adult use, but whether it suits a particular person is a decision for a clinician experienced in HIV care. Factors that can shape that discussion include:
Indinavir is not recommended for children because its safety, effectiveness and an appropriate paediatric dosing schedule have not been established. Paediatric studies also found a substantially higher rate of kidney stones than in adults, while raised bilirubin is an additional concern in newborns.
Indinavir blocks HIV protease, an enzyme the virus uses to cut long protein chains into the functional components needed to assemble new infectious viral particles. Blocking this step helps limit viral replication when Indinavir is combined with antiretroviral medicines that act at other stages of the viral life cycle.
The practical issue is maintaining adequate medicine levels by taking every dose as prescribed. A high-calorie or high-fat meal can reduce Indinavir absorption. It is therefore generally taken on an empty stomach or with a light meal, according to the directions provided by the prescriber and product information. Patients should not invent their own meal schedule or alter the dose to compensate for food.
Some alternative protease-inhibitor regimens use a booster medicine such as ritonavir and have different food instructions. That can make them easier for some people to align with meals, although boosted regimens also introduce their own interactions and adverse-effect considerations. Meal timing is therefore one practical comparison point rather than a reason to prefer one medicine automatically.
A workable daily routine matters because inconsistent dosing or food timing can reduce exposure to Indinavir. Before starting treatment, the following points should be agreed with the prescriber or pharmacist:
Capsules should remain in the original container rather than being transferred to an unprotected organiser for long periods. If the container has been left open, the desiccant is missing or the capsules appear affected by moisture, a pharmacist should be consulted before they are used.
We offer Indinavir as 400 mg oral capsules in packs of 30 or 60 capsules. Both pack sizes contain the same strength and dosage form. The package quantity does not change how the medicine should be taken, and it should not be used to infer a dose or a fixed number of treatment days.
The appropriate quantity depends on the prescribed regimen and plans for continued clinical review. A 60-capsule pack may reduce how often an order needs to be arranged, while a 30-capsule pack provides a smaller quantity. Either choice should remain aligned with the prescribed dosing schedule and the supply of every other medicine in the combination.
A combination regimen containing Indinavir is intended to reduce the amount of HIV in the blood and support immune function over ongoing treatment. It is not expected to produce a noticeable benefit after a single dose, and Indinavir does not cure HIV. The response is assessed through clinical review and laboratory monitoring rather than symptoms alone.
The timing and degree of viral-load reduction vary according to the complete regimen, the virus's susceptibility to its components and how consistently treatment is taken. Meal timing can also affect Indinavir exposure. Because the medicine is always used with other antiretroviral agents, its contribution cannot be separated reliably from the response to the regimen as a whole.
A clinician normally reviews viral load, immune markers, adverse effects and relevant blood or urine results. A lack of noticeable symptoms is not a reason to stop treatment, while an unexpected result does not justify changing the dose without clinical advice. Treatment interruptions can permit viral replication and increase the risk of resistance.
Several safety considerations are particularly relevant when comparing Indinavir with other protease inhibitors:
These priorities complement the detailed product safety information rendered separately. They are decision factors rather than a complete list of adverse effects or reasons to stop treatment. New, severe or persistent symptoms should be discussed with a clinician or pharmacist.
Indinavir is processed through liver-enzyme pathways used by many other medicines. An interacting medicine can lower Indinavir levels and reduce its effectiveness, or raise its levels and increase adverse effects. Indinavir can also alter the levels of another medicine. Some combinations are contraindicated, while others require dose adjustment or closer monitoring.
A prescriber or pharmacist should review a complete and current list of prescription medicines, non-prescription products, vitamins and herbal supplements before Indinavir is started and whenever another treatment changes. This review should include medicines used only occasionally. St John's wort and other strong enzyme-inducing products are particularly important to disclose because they can reduce exposure to some antiretroviral medicines.
Nevirapine is an example of another antiretroviral medicine that can affect drug-metabolising enzymes and lower Indinavir exposure. It should not be added casually or treated as an interchangeable companion medicine. If both medicines are being considered, the clinician must assess the interaction and determine an appropriate regimen.
Patients should also report liver or kidney problems and any previous severe medicine reaction. Capsules contain anhydrous lactose, which may be relevant to a person with lactose intolerance even though intolerance is different from a medicine allergy.
Indinavir is one of several protease inhibitors, and alternatives differ in food requirements, dosing frequency, use of a booster medicine, interaction profile and adverse effects. Atazanavir may be used with a booster in many regimens but can be used differently in selected circumstances. Lopinavir is supplied with ritonavir as a boosted combination. Their dosing and food instructions differ from those for Indinavir.
Darunavir, fosamprenavir and tipranavir have sulfonamide structural components that Indinavir does not. That distinction can be discussed when allergy history is relevant, but it does not prove that a person will react to one medicine or tolerate another. Saquinavir and nelfinavir have their own dosing, availability, safety and interaction considerations. None is a direct capsule-for-capsule substitute for Indinavir.
Comparing indinavir and dolutegravir
Key feature Indinavir Dolutegravir Active ingredient Indinavir Dolutegravir Medicine class Protease inhibitor (PI) Integrase strand transfer inhibitor (INSTI) Primary use HIV-1 infection (part of combination therapy) HIV-1 infection (part of combination therapy) Dosage form Capsules Tablets Available strengths 400 mg 50 mg Typical dosing Every 8 hours Once daily
For someone comparing a ritonavir-boosted option, Kaletra contains lopinavir and ritonavir. Its food instructions, interaction profile and dosing pattern differ from those of Indinavir, so the practical fit may be different. A prescriber should compare complete regimens rather than selecting a protease inhibitor on one feature alone.
Indinavir is a Schedule 4 prescription-only medicine in Australia. Its legal classification is separate from our ordering process: our current policy does not require a prescription to be provided when an order is placed, but that administrative policy does not change Indinavir's Schedule 4 status or replace assessment and prescribing by an appropriately qualified clinician.
Registration on the Australian Register of Therapeutic Goods is specific to the product and sponsor. The current ARTG status of a particular Indinavir 400 mg capsule product should therefore be confirmed before supply rather than inferred from the active ingredient or dosage form alone. Suspected adverse events can be reported to the Therapeutic Goods Administration.
Anyone considering Indinavir should have a treating clinician oversee the complete HIV regimen and the monitoring it requires. Our support team can clarify our ordering process, but it cannot replace diagnosis, prescribing or ongoing HIV care.
When arranging an order, first select the listed pack size of 30 or 60 capsules and check that it matches the quantity planned with the treating clinician. Orders are handled in Australian dollars. Customers should then provide accurate contact and delivery details and review the order before submission.
Our pharmacist-supported team is available 24/7 by phone, online chat and email to answer questions about the product, ordering process and available delivery arrangements. Because no specific delivery timeframe is supplied for this product, treatment planning should not rely on an assumed arrival date. Ordering early enough to address questions or delays can help reduce the risk of an avoidable interruption, but any urgent continuity-of-treatment concern should be raised with the treating clinician or a local pharmacist.
The decision about Indinavir 400 mg capsules comes down to several concrete factors: whether its food-timing instructions fit the daily routine, whether kidney-stone and blood-glucose risks can be managed, whether interactions affect the wider regimen and whether the absence of the sulfonamide structure found in some other protease inhibitors is clinically relevant. Pack size is a supply choice, not a substitute for deciding whether the medicine itself is suitable.
No single feature makes Indinavir the best option for everyone. A treating clinician should compare it with other protease inhibitors and with the complete range of antiretroviral combinations appropriate to the person's treatment and resistance history. Readers exploring medicines from different antiretroviral classes can use our HIV category as a catalogue starting point, while relying on clinical advice to determine which products belong in an individual regimen.
Will the indinavir package include an English leaflet?
The leaflet language for the supplied package is not confirmed in advance and may vary. Check the package and leaflet when it arrives; do not rely on instructions you cannot read, and ask a pharmacist or clinician for help interpreting them if needed.
I drive a delivery van for work and have just started indinavir. Is it safe to drive after taking the capsules?
Indinavir can cause dizziness or blurred vision in some people. Do not drive or operate machinery if you notice either effect, and wait until you feel fully alert and your vision is clear.
| Active ingredient | Indinavir |
|---|---|
| Drug class | HIV protease inhibitor |
| Dosage form | Capsules |
| Available strengths | 400 mg |
| Route | Oral |
| Storage | Store at 15°C to 30°C in the original tightly closed container with its desiccant to protect the capsules from moisture. |
| ATC code | J05AE02 |
This product has 5 ratings, but only 4 written reviews so far. Share your experience and help other customers.
Very happy with the generic.
Easy order to place.
It arrived within the expected delivery period.
Indinavir order dispatched quickly.
